Stock Code: 002750 stock abbreviation: Kunming Longjin Pharmaceutical Co.Ltd(002750) Announcement No.: 2021-063 Kunming Longjin Pharmaceutical Co.Ltd(002750)
Stock trading abnormal fluctuation announcement
The company and all members of the board of directors guarantee that the information disclosed is true, accurate and complete without false records, misleading statements or major omissions.
1、 Description of abnormal fluctuations in stock trading
The deviation of the closing price increase of Kunming Longjin Pharmaceutical Co.Ltd(002750) (hereinafter referred to as “the company”) stock (securities code: 002750, securities abbreviation: Kunming Longjin Pharmaceutical Co.Ltd(002750) ) in two consecutive trading days (December 23 and December 24, 2021) has reached 21.12% in total. According to the trading rules of Shenzhen Stock exchange, it belongs to abnormal fluctuation of stock trading.
2、 Description of concerns and verification on important issues
In view of the abnormal fluctuation of this stock transaction, the company checked the relevant matters and consulted the controlling shareholder and actual controller of the company in writing. The relevant information is described as follows:
1. The controlling shareholders and actual controllers do not have any major matters that should be disclosed but not disclosed about the company, nor do they have any major matters in the planning stage;
2. The controlling shareholders and actual controllers do not buy or sell the company’s shares during the abnormal fluctuation of stock trading;
3. The company’s recent operation is normal, the internal and external business environment has not changed significantly, and there are no major events that should be disclosed but not disclosed at present;
4. Recently, the public media have not reported any unpublished material information that may have a great impact on the company’s stock trading price.
3、 Description of no information that should be disclosed but not disclosed
On December 23, 2021, the company disclosed the announcement on participating in the planned winning of centralized volume procurement of inter provincial alliance of Chinese patent medicines (Announcement No.: 2021-062), the company plans to select breviscapine for injection for centralized volume procurement of inter provincial alliance of finished drugs. The selection results and prices of this centralized volume procurement are still uncertain. The relevant procurement contracts for the products to be selected have not been signed, the agreed procurement volume has not been clarified, and the subsequent matters and the impact on the company are still uncertain.
The board of directors of the company confirms that the company has no other matters that should be disclosed but not disclosed in accordance with the relevant provisions of the stock listing rules of Shenzhen Stock Exchange or the planning, negotiation, intention and agreement related to the matter; The board of directors has not learned that the company has undisclosed information that has a great impact on the company’s stock trading price in accordance with the stock listing rules of Shenzhen Stock Exchange and other relevant provisions; There is no need to correct or supplement the information disclosed by the company in the early stage.
4、 Risk tips deemed necessary by the company
1. The company’s information disclosure does not violate fair information disclosure.
2. The board of directors of the company solemnly reminds investors: China Securities Journal, securities times and cninfo（ http://www.cn.info.com..cn./ ）For the information disclosure media selected by the company, all information of the company shall be subject to the information published in the above designated media. Please refer to the information disclosed by the company, make rational investment and pay attention to investment risks.
5、 Documents for future reference
1. Analysis and explanation of the board of directors on abnormal fluctuations in stock trading;
2. Inquiry letter and reply from the board of directors to the controlling shareholder and actual controller.
It is hereby announced.
Kunming Longjin Pharmaceutical Co.Ltd(002750) board of directors December 24, 2021
